Uploaded August 2024 | Updated November 2026, 3 hours ago
Abby was initially diagnosed with transverse myelitis in 2006 and later re-diagnosed with acute flaccid myelitis in 2019. Her journey highlights the evolving nature of diagnosis and the enduring spirit required to face such challenges.
Abby was initially diagnosed with transverse myelitis in 2006 and later re-diagnosed with acute flaccid myelitis in 2019. Her journey highlights the evolving nature of diagnosis and the enduring spirit required to face such challenges.
![2026 RNDS | State of the Science Across Rare Neuroimmune Disorders and Clinical Trials Panel
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital and Benjamin Greenberg, MD, MHS, of the University of Texas Southwestern talked through the state of the science across rare neuroimmune disorders and clinical trials [00:00:05]. They started with epidemiology maps, what they can show about possible genetic hotspots, and why a place with no dots may simply lack access to antibody testing [00:00:57]. They discussed how genetics, environment, and timing may combine to cause these disorders [00:05:15], then how immune activity outside the nervous system may move in and out of it [00:07:48]. They explained why antibodies are more complicated than a single positive test, and how an antibody can be present during remission [00:10:46]. They covered MRI, blood tests, false negatives, and spinal fluid testing [00:20:24], and closed with MOGAD trials, insurance case managers, future therapies, and audience questions [00:31:38].
Benjamin Greenberg, MD, MHS, is Director of the Perot Foundation Neurosciences Translational Research Center within the ODonnell Brain Institute and Vice Chair of Translational Research for the Department of Neurology at University of Texas Southwestern Medical Center. He directs the Transverse Myelitis and Neuromyelitis Optica Program and established the Pediatric Demyelinating Disease Program at Childrens Medical Center Dallas in 2009. He is recognized internationally as an expert in rare autoimmune disorders of the central nervous system.
Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
00:00 Welcome and Panel Introductions
00:57 Epidemiology and Global Maps
05:15 Genetics, Environment, and Timing
07:48 How These Disorders Develop
10:46 Why Antibodies Are Complicated
16:25 Antibodies and Remission
20:24 MRI in Daily Care
24:39 Blood Tests and Antibody Assays
29:44 Spinal Fluid Testing
31:38 Clinical Trials Overview
33:58 Trials and Treatment Decisions
39:44 Insurance Case Managers
41:12 Future Therapies
42:54 Audience Questions and Closing 2026 RNDS | State of the Science Across Rare Neuroimmune Disorders and Clinical Trials Panel](https://i.ytimg.com/vi/CGXa2UX81l8/mqdefault.jpg)


![2026 RNDS | Pain and Sensory Symptoms Toolkit
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Shuvro Roy, MD, of the University of Washington, offered a pain and sensory symptoms toolkit for people to use with their own physicians [00:01:10]. He reviewed how common pain is, including up to 86% of people with seropositive neuromyelitis optica spectrum disorder (NMOSD), about 70% of people with MOG antibody disease (MOGAD) during an attack, and 80 to 94% of people with transverse myelitis (TM) reporting sensory symptoms [00:03:27]. Dr. Roy explained neuropathic, nociceptive, and nociplastic pain, along with numbness, allodynia, banding (the hug), painful tonic spasms, Lhermittes sign, and eye pain, head pain, and trigeminal neuralgia [00:05:16]. He described how to talk about pain beyond a number, and which changes in pain, together with new weakness, vision loss, or bowel and bladder changes, are reasons to call the care team [00:15:01]. He closed with treatment options, non-drug approaches such as physical therapy, occupational therapy, sleep, and pain psychology, resources, and building a care team [00:18:28].
Shuvro Roy, MD, is an Assistant Professor of Neurology at the University of Washington, specializing in neuroimmunology, with a specific focus on multiple sclerosis (MS) and related neuroimmunologic disorders. He is Co-Director of the UW SRNA Center of Excellence for Rare Neuroimmune disorders. He completed his neuroimmunology and neuroinfectious disease fellowship at Johns Hopkins University, graduated from medical school at Ohio State University, and completed his neurology residency at the University of California, Los Angeles. Dr. Roy is engaged in projects to improve access to care, address healthcare disparities, and enhance patient safety for people living with MS and related conditions, with a special interest in neuromyelitis optica and MOG antibody disease.
00:00 Introduction to Dr. Roy
01:10 Welcome and Session Goals
02:57 Why Pain Matters
03:27 How Common Pain Is
05:16 Types of Pain
06:44 Other Sensory Symptoms
08:14 Where Damage Shapes Pain
10:16 Face, Head, and Eye Pain
12:36 Pain Over Time
15:01 How to Talk About Your Pain
17:21 When Pain May Signal an Attack
18:28 Treatment Options
20:15 Non-Drug Strategies and Resources 2026 RNDS | Pain and Sensory Symptoms Toolkit](https://i.ytimg.com/vi/DTzrmqgczuY/mqdefault.jpg)


![Ask the Expert 1404. MOGcast | The State of MOGAD Science
In this special “Ask the Expert” collaboration between The MOG Project and SRNA, Julia Lefelar and Dr. GG deFiebre welcomed Dr. Benjamin Greenberg of UT Southwestern, who answered questions from the audience. Dr. Greenberg reviewed major advances in MOG antibody disease research and diagnostic criteria [00:05:06]. He discussed efforts to predict relapse risk using sustained antibody positivity, demographic and clinical models, and immune-cell profiling studies [00:07:55]. Dr. Greenberg detailed controversies around low-positive antibody titers and how cell-based assays and dilution thresholds affect specificity [00:21:38]. He outlined concepts and progress in tolerance-inducing approaches such as Tregs and CAR T therapy, described differences from B-cell–depleting drugs like rituximab [00:26:32] Finally, Dr. Greenberg highlighted the satralizumab meteoroid trial and the ongoing cosMOG study of rozanolixizumab, emphasizing community engagement, registries, surveys, and trial participation to accelerate access and potential curative strategies [00:38:36]. You can learn more about The MOG Project here:
https://mogproject.org/
Benjamin M. Greenberg, MD, MHS is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology [ https://utswmed.org/why-utsw/departments/neurology/ ] at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center [ https://utswmed.org/locations/aston/multiple-sclerosis-and-neuroimmunology-clinic/ ] and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children’s Medical Center [ https://www.childrens.com/specialties-services/specialty-centers-and-programs/neurology/demyelinating-disease-program ].
Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago’s Rush Presbyterian-St. Luke’s Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor’s degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation’s first dedicated Transverse Myelitis Center.
Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children’s Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients.
00:00 Welcome
01:44 Hosts and Guest Intro
05:06 Research Buckets Overview
07:55 Predicting Relapse Risk
11:46 Tregs and Immune Brakes
17:40 Attack Severity and Relapse
19:24 MOGAD Criteria Updates
21:38 Titers Explained Simply
26:32 Targeting MOG Antibodies
29:11 CAR T and Immune Reset
32:39 When Criteria Changes
33:52 Tolerance Research Boom
34:48 From Animals to Trials
37:17 Community Drives Progress
38:36 Meteoroid and cosMOG Clinical Trials
41:39 How These Drugs Work
44:02 FDA Approval and Access
45:49 Insurance Switch Concerns
48:39 Rituximab Dosing Debate
52:41 Why Antibodies Develop
54:18 Future Attack Patterns
55:47 CAR T Versus Rituximab
57:10 Lab Research and Support
01:00:51 Hope for a Cure
01:02:14 Closing and Resources Ask the Expert 1404. MOGcast | The State of MOGAD Science](https://i.ytimg.com/vi/EJuZIJ59s4g/mqdefault.jpg)
![1309. Parenting is Hard | Part 5
At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submit
In part five of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA was joined by Barbara Babcock to further explore her research concerning the changing beliefs around parenting when a child has been diagnosed with a rare neuroimmune disorder. They explored the theme of finding a balance in attending to the needs of all children in the family and discussed the importance of fairness and communication between parents [00:02:18]. The conversation also touched on the cultural differences and how these influence family dynamics and parenting strategies when one child requires more attention [00:13:33]. Barbara shared various strategies families use to ensure each child feels valued, such as integrating quality time into existing routines and understanding the different needs of children at various developmental stages [00:18:30].
Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdoms National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at Kings College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk
00:00 Introduction
00:28 Meet the Expert: Barbara Babcock
02:18 Theme Three: Balancing Sibling Needs
03:59 Parental Communication and Mutual Support
13:33 Cultural and Family Contexts
18:30 Building Quality Time with Siblings
26:13 Parental Guilt and Compensation
35:09 Conclusion 1309. Parenting is Hard | Part 5](https://i.ytimg.com/vi/EYet3CWzmjc/mqdefault.jpg)
![1301. Vaccines and Immunosuppression
In this episode of Ask the Expert, Dr. Eoin Flanagan joined Dr. GG deFiebre of SRNA. Dr. Flanagan explained how immunosuppressive medications impact the immune system and the efficacy of vaccines [00:02:45]. He discussed the primary concerns and risks of vaccinating individuals on these therapies, including avoiding live vaccines and the need for additional booster doses [00:04:52]. Dr. Flanagan also talked about the recommended vaccines for those with conditions like MOG antibody disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD), and underlined the importance of getting vaccinated to prevent severe infections [00:09:40]. He addressed common misconceptions and emphasized the role of healthcare providers in educating and supporting their patients regarding vaccinations [00:15:32].
Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a masters in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder.
00:00 Introduction
00:47 Understanding Immunosuppressants and Vaccines
01:28 Primary Concerns with Vaccinating Immunosuppressed Patients
02:30 Recommended Vaccines for Immunosuppressed Patients
07:11 Timing and Effectiveness of Vaccinations
08:21 Measuring Vaccine Response
09:24 Addressing Missed Doses and Safety Considerations
16:41 Public Health Implications and Patient Advocacy
17:56 Advice for Vaccine-Hesitant Patients
19:06 Healthcare Providers Role in Vaccination
20:03 Conclusion and Final Thoughts 1301. Vaccines and Immunosuppression](https://i.ytimg.com/vi/EbxPN2XXaRM/mqdefault.jpg)
![2024 RNDS | Community Perspectives Panel: Navigating Work, Travel, Setting Boundaries, and More
At the 2024 RNDS, this panel of community members discussed the benefits of setting boundaries while travelling and with colleagues, family members, and friends [00:00:10]. Rebecca Salky shared her journey on learning to say no and prioritizing her rest [00:01:12]. Philip Rive highlighted the challenges of accepting limited capacities and focusing on quality over quantity [00:03:24]. Leah Campbell emphasized the importance of time management and clear communication about invisible disabilities [00:06:45]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction to Community Perspectives
00:24 The Importance of Setting Boundaries
01:00 Personal Experiences with Boundaries
03:13 Invisible Disabilities and Communication Challenges
07:10 Navigating Work with Health Conditions
11:56 Adapting to Changes and Finding Balance
16:34 Travel Challenges and Solutions
23:18 Living Life to the Fullest Despite Limitations
25:18 Conclusion and Final Thoughts 2024 RNDS | Community Perspectives Panel: Navigating Work, Travel, Setting Boundaries, and More](https://i.ytimg.com/vi/F1olXRYdBcY/mqdefault.jpg)
![2026 RNDS | TIMELY-PLEX Study
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), John J. Chen, MD, PhD, of Mayo Clinic, speaking remotely from Minnesota, described TIMELY-PLEX, a trial testing whether plasma exchange (PLEX) improves recovery after severe optic neuritis or myelitis [00:00:05]. He reviewed standard treatment with high-dose IV steroids, what PLEX involves, and why earlier studies of PLEX may look better than they are [00:01:10]. He explained the design: everyone receives steroids, and people are randomized to PLEX right away or to PLEX only if they have not recovered after 7 to 14 days, with almost 400 people at more than 30 US centers [00:05:52]. Dr. Chen covered who can join, including adults within 14 days of symptom onset, and the outcomes measured [00:07:57]. Michael Levy read questions on timing with steroids, MRI confirmation, telling a stroke from inflammation, and results by disease type [00:17:26].
John J. Chen, MD, PhD, is a neuro-ophthalmologist and Professor of Ophthalmology and Neurology at Mayo Clinic. He provides care for people with visual disorders related to neurological causes and works closely with neurology, rheumatology, and neurosurgery. Dr. Chen completed his MD and PhD at the University of Virginia and his ophthalmology residency and neuro-ophthalmology fellowship at the University of Iowa before joining Mayo Clinic in 2014. His clinical and research focus includes optic neuritis (MOG antibody disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and multiple sclerosis), idiopathic intracranial hypertension, and neuro-ophthalmic imaging. He serves as Neuro-Ophthalmology Fellowship Director and is co-lead investigator of the TIMELY-PLEX trial, a PCORI-funded multicenter clinical trial of plasma exchange for acute optic neuritis across more than 30 US sites. He is an Associate Editor for Ophthalmology and the Journal of Neuro-Ophthalmology and has published more than 300 peer-reviewed articles.
Dr. Chen serves as Vice President of the North American Neuro-Ophthalmology Society (NANOS) and previously served as President of the Minnesota Academy of Ophthalmology and Chair of the Upper Midwest Neuro-Ophthalmology Group. He is a member of the American Ophthalmological Society and the American Eye Study Club and serves as an Oral Board Examiner for the American Board of Ophthalmology. His awards include the AAO Senior Achievement Award, the Real World Ophthalmology Inspiring Academic Leader Award, four-time Mayo Clinic Ophthalmology Teacher of the Year leading to induction into the Educators Hall of Fame, and the Mayo Clinic Distinguished Educator Award.
00:00 Introduction to TIMELY-PLEX
01:10 Standard Treatment and PLEX
03:16 Why Earlier Studies Can Mislead
05:24 How the Trial Is Designed
07:57 Who Can Join
08:56 Vision and Spinal Cord Criteria
11:56 Masked Evaluators and Safety
12:54 Outcomes That Matter
14:02 How to Refer Someone
15:06 Take-Home Messages
17:26 Audience Questions
22:21 Results by Disease Type and Closing 2026 RNDS | TIMELY-PLEX Study](https://i.ytimg.com/vi/FJ84Xjk6IeI/mqdefault.jpg)